RLYB — Rallybio Income Statement
0.000.00%
Last trade - 00:00- $44.64m
- -$10.09m
- $0.86m
Annual income statement for Rallybio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 0 | 0.636 | 0.858 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 47.2 | 69 | 81 | 63.4 | 34.8 |
| Operating Profit | -47.2 | -69 | -81 | -62.7 | -33.9 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -47 | -66.7 | -74.6 | -57.8 | -8.98 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -47 | -66.7 | -74.6 | -57.8 | -8.98 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -47 | -66.7 | -74.6 | -57.8 | -8.98 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Dilution Adjustment | |||||
| Diluted Net Income | -47 | -66.7 | -74.6 | -57.8 | -8.98 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -14.3 | -16.5 | -14.3 | -10.2 | -1.44 |